Skip to main content

Table 1 Summary of the retrieved studies investigating pre-treatment C-reactive protein to albumin ratio on survival in colorectal cancer patients

From: Prognostic value of the C-reactive protein to albumin ratio in colorectal cancer: an updated systematic review and meta-analysis

Author Year Country Tumor Location Sample size Gender, M:F Age (years) Stage Treatment Cut-off value Outcome HR 95% CI Follow-up time Analysis NOS score
Ishizuka 2016 Japan CRC 627 400:227 NA 0–IV Surgery 0.038 OS 2.596 1.603–4.204 NA MV 8
Shibutani 2016 Japan CRC 99 57:42 63 (27–86) IV Chemotherapy 0.183 OS 1.866 1.057–3.295 2.6–73.2 MV 8
Shibutani 2016 Japan CRC 705 411:294 68 (26-90) I–III Surgery 0.0278 DFS
CSS
1.503 1.672 1.054–2.143
1.012–2.764
NA MV 8
Solaini 2016 UK CRLM 194 125:69 66 (59-73) IV Liver resection 0.133 OS 2.04 1.26–3.3 NA UV 7
Haruki 2017 Japan CRLM 106 76:30 64.5 (39-87) IV Liver resection 0.04 OS
DFS
2.559 1.731 1.420–4.613
1.087–2.758
NA MV 8
Ide 2017 Japan Rectum 115 82:33 64 (33–83) I–III Surgery 0.049 OS
DFS
5.09
4.98
2.31–11.58
2.34–11.14
65 (2–189) MV 8
Dolan 2018 UK Colon 801 430:371 NA I–III Surgery 0.22 OS
CSS
1.84 1.76 1.49–2.26
1.31–2.35
NA MV 7
Climent 2019 Ireland CRC 566 260:306 69.9 ± 12.3 I–III Surgery 0.46 OS
DFS
1.84 1.73 1.1–3.1
0.8–3.3
NA UV 6
Shibutani 2019 Japan CRC 40 25:15 NA IV Chemotherapy 0.122 OS
PFS
6.478 4.525 1.374–30.537
0.826–24.794
NA MV 8
Sakamoto 2020 Japan CRLM 184 121:63 63.1 (25-94) IV Liver resection 0.093 OS
PFS
2.82 1.62 1.63–4.72
1.02–2.49
NA MV 8
Son 2020 Korea CRC 789 486:283 NA I–III Surgery 0.14 OS 1.97 1.47–2.64 91 (67–115) UV 7
Suzuki 2020 Japan Colon 1303 689:614 65 (26-93) II–III Surgery 0.02558 OS
DFS
1.8
1.28
1.24–2.68
0.99–1.66
60.2 (3–106) MV 8
Ni 2016 china CRC 148 97:51 NA IV Chemotherapy 0.6712 OS 2.243 1.450–3.470 NA MV 8
Zhou 2018 china CRC 516 331:185 NA I–IV Surgery 0.07/0.08 OS
DFS
1.59 1.05 0.86–2.91
0.71–1.56
21.72 (2.11–118.72) MV 8
Tominaga 2016 Japan Colon 136 79:57 NA III Chemotherapy 0.1 DFS 4.43 1.94–10.15 NA UV 7
  1. CRC colorectal cancer, CRLM colorectal cancer liver metastasis, MV multivariate, UV univariate, OS overall survival, DRS disease-free survival, CSS cancer-specific survival, PFS progression-free survival